The company will be launching dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets — which are mixed salts of a single entity amphetamine product — in 5mg, 10mg, 15 mg, 20 mg, 30 mg strengths.
The drug is the bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets, of the same strengths, of Teva Women’s Health, Inc. According to a US government website Medline Plus
, Adderall is used for the treatment of ADHD and narcolepsy.
As per the IQVIA sales data for a year till February 2025, the Adderall tablets in the mentioned strengths witnessed annual sales of around $421.7 million.
“Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch,” Marc Kikuchi, President and Business Head, North America said. He added that the medicine is a highly-prescribed one in the United States.
Glenmark Pharma shares ended the previous session 1.61% lower at ₹1,354.8 apiece. The stock has declined nearly 22% in the last six months.
Also Read: Sonata Software shares in focus after international business revenue warning
First Published: Apr 17, 2025 7:55 AM IST
